Bullous Pemphigoid: Insights and Innovations

Experience this engaging presentation by Dr. Donna Culton, Prof. Dédée Murrell, and Prof. Ulrike Raap, who highlight the heterogeneous clinical presentations of BP and its burden, delve beneath the surface into how autoimmunity and predominantly type 2 inflammation mediate the disease, and explore the evolving toolbox of current approaches in BP management.

Department of Dermatology University of New South Wales

MD, PhD

Donna Aline Culton +2 more

On demand materials

Recognizing BP and Understanding Its Toll

Dermatology

10 min

expert video

Recognizing BP and Understanding Its Toll

Beneath the Surface: How Autoimmunity and Predominantly Type 2 Inflammation Mediate BP

Dermatology

10 min

expert video

Beneath the Surface: How Autoimmunity and Predominantly Type 2 Inflammation Mediate BP

Bullous Pemphigoid: Insights and Innovation

Dermatology

45 min

expert video

Bullous Pemphigoid: Insights and Innovation

Dermatology

10 min

expert video

The Evolving Toolbox: Current Approaches in BP Management

Learning objectives

Discuss the complexity of BP clinical presentation, diagnostic challenges, and patient management
Explore the roles of autoimmunity and inflammatory pathways, including type 2, underlying the pathophysiology of BP
Assess the current treatment landscape in BP

About these experts

Dermatology

MD, PhD

Donna Aline Culton

Professor of Dermatology Associate Director, Clinical Trials Unit Director, Clinical Immunofluorescence Laboratory  University of North Carolina, Chapel Hill Chapel Hill, NC, USA

Dermatology

MD, FAAD, MA, BMBCh, DSc

Dédée Murrell

Professor, Faculty of Medicine Head, Department of Dermatology University of New South Wales St. George Hospital Sydney, Australia

Dermatology

Ulrike Raap

Professor, Department of Experimental Allergology and Immunodermatology, University Department of Dermatology and Allergology, Carl von Ossietzky University of Oldenburg

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: MalaysiaChange country/region